{"id":"https://openalex.org/W4361947554","doi":"https://doi.org/10.1158/1078-0432.c.6526829","title":"Data from Metastatic Melanoma Patient\u2013Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition","display_name":"Data from Metastatic Melanoma Patient\u2013Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361947554","doi":"https://doi.org/10.1158/1078-0432.c.6526829"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6526829","doi":"https://doi.org/10.1158/1078-0432.c.6526829","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6526829","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.6526829","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001839705","display_name":"Rebecca L. Shattuck-Brandt","orcid":"https://orcid.org/0000-0003-2163-3221","observed_orcids":["https://orcid.org/0000-0003-2163-3221"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rebecca L. Shattuck-Brandt","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2163-3221","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059563188","display_name":"Sheau\u2010Chiann Chen","orcid":"https://orcid.org/0000-0002-5574-1434","observed_orcids":["https://orcid.org/0000-0002-5574-1434"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sheau-Chiann Chen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5574-1434","affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Emily Murray","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emily Murray","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102868164","display_name":"Christopher Andrew Johnson","orcid":"https://orcid.org/0000-0003-1376-546X","observed_orcids":["https://orcid.org/0000-0003-1376-546X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher Andrew Johnson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075088828","display_name":"Holly Crandall","orcid":"https://orcid.org/0009-0009-3763-3892","observed_orcids":["https://orcid.org/0009-0009-3763-3892"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Holly Crandall","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004659977","display_name":"Jamye F. O\u2019Neal","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jamye F. O'Neal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055625321","display_name":"Rami Nayef Al-Rohil","orcid":"https://orcid.org/0000-0002-9431-0530","observed_orcids":["https://orcid.org/0000-0002-9431-0530"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rami Nayef Al-Rohil","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9431-0530","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037844360","display_name":"Caroline A. Nebhan","orcid":"https://orcid.org/0000-0002-9402-7284","observed_orcids":["https://orcid.org/0000-0002-9402-7284"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Caroline A. Nebhan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009398473","display_name":"Vijaya Bharti","orcid":"https://orcid.org/0000-0002-0970-6988","observed_orcids":["https://orcid.org/0000-0002-0970-6988"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vijaya Bharti","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0970-6988","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046499856","display_name":"Kimberly Brown Dahlman","orcid":"https://orcid.org/0000-0002-7819-6571","observed_orcids":["https://orcid.org/0000-0002-7819-6571"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kimberly B. Dahlman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013233073","display_name":"Gregory Dan Ayers","orcid":"https://orcid.org/0000-0002-0892-350X","observed_orcids":["https://orcid.org/0000-0002-0892-350X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gregory D. Ayers","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007111794","display_name":"Chi Wing Yan","orcid":"https://orcid.org/0000-0002-8658-7302","observed_orcids":["https://orcid.org/0000-0002-8658-7302"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chi Yan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103506387","display_name":"Mark C. Kelley","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark C. Kelley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042796069","display_name":"Rondi Marie Kauffmann","orcid":"https://orcid.org/0000-0002-8391-411X","observed_orcids":["https://orcid.org/0000-0002-8391-411X","https://orcid.org/0000-0003-0146-4635"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rondi M. Kauffmann","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013565834","display_name":"Mary A. Hooks","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mary Hooks","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012025404","display_name":"Ana M. Grau","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ana Grau","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025067315","display_name":"Douglas Buckner Johnson","orcid":"https://orcid.org/0000-0002-6390-773X","observed_orcids":["https://orcid.org/0000-0002-6390-773X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Douglas B. Johnson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060947046","display_name":"Anna E. Vilgelm","orcid":"https://orcid.org/0000-0002-4446-913X","observed_orcids":["https://orcid.org/0000-0002-4446-913X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna E. Vilgelm","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5010542605","display_name":"Ann J. Richmond","orcid":"https://orcid.org/0000-0002-9580-900X","observed_orcids":["https://orcid.org/0000-0002-9580-900X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ann Richmond","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9580-900X","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9814000129699707,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9814000129699707,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.010099999606609344,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9940000176429749},{"id":"https://openalex.org/keywords/mdm2-inhibition","display_name":"MDM2 inhibition","score":0.906000018119812},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.9079999923706055},{"id":"https://openalex.org/keywords/braf-mek-inhibitors","display_name":"BRAF/MEK inhibitors","score":0.7870000004768372},{"id":"https://openalex.org/keywords/p53-stabilization","display_name":"p53 stabilization","score":0.6959999799728394},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.8610000014305115},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6549999713897705},{"id":"https://openalex.org/keywords/cdkn2a-loss","display_name":"CDKN2A loss","score":0.7760000228881836},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-resistance","display_name":"immune checkpoint inhibitor resistance","score":0.6919999718666077}],"concepts":[{"id":"https://openalex.org/C21790070","wikidata":"https://www.wikidata.org/wiki/Q18030215","display_name":"Neuroblastoma RAS viral oncogene homolog","level":5,"score":0.7956267595291138},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.7350013256072998},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6611109972000122},{"id":"https://openalex.org/C2780265364","wikidata":"https://www.wikidata.org/wiki/Q5009957","display_name":"CDKN2A","level":3,"score":0.6603886485099792},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.5657647848129272},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.5616443157196045},{"id":"https://openalex.org/C2776192174","wikidata":"https://www.wikidata.org/wiki/Q18028978","display_name":"Mdm2","level":3,"score":0.540505588054657},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.4914959669113159},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4795915186405182},{"id":"https://openalex.org/C2779707156","wikidata":"https://www.wikidata.org/wiki/Q5611758","display_name":"Growth inhibition","level":3,"score":0.4388244152069092},{"id":"https://openalex.org/C134459356","wikidata":"https://www.wikidata.org/wiki/Q4274835","display_name":"Ubiquitin ligase","level":4,"score":0.43570172786712646},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3532009422779083},{"id":"https://openalex.org/C25602115","wikidata":"https://www.wikidata.org/wiki/Q407111","display_name":"Ubiquitin","level":3,"score":0.3529994487762451},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.2785307765007019},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2769213318824768},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.2460053265094757},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.22920799255371094},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.21616163849830627},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.2008405327796936},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.08939474821090698},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.08683454990386963},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.6526829","doi":"https://doi.org/10.1158/1078-0432.c.6526829","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6526829","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6526829","doi":"https://doi.org/10.1158/1078-0432.c.6526829","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6526829","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9907000064849854}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3014641112","https://openalex.org/W4362404242","https://openalex.org/W2278296177","https://openalex.org/W2617846385","https://openalex.org/W1575813227","https://openalex.org/W4392688669","https://openalex.org/W2276308766","https://openalex.org/W2887342233","https://openalex.org/W2046585589","https://openalex.org/W2056235437"],"abstract_inverted_index":{"AbstractPurpose:":[0],"Over":[1,44],"60%":[2],"of":[3,46,51,65,71,80,88,92,104,125,174,215,229],"patients":[4,141],"with":[5,96,109,116,142,147,152,192,240],"melanoma":[6,47,95],"respond":[7],"to":[8,56,130,186,201,212],"immune":[9],"checkpoint":[10],"inhibitor":[11,99,112],"(ICI)":[12],"therapy,":[13],"but":[14,30],"many":[15],"subsequently":[16],"progress":[17],"on":[18,26],"these":[19],"therapies.":[20],"Second-line":[21],"targeted":[22],"therapy":[23,225],"is":[24,222],"based":[25],"BRAF":[27,57,153,193,241],"mutation":[28,64,160],"status,":[29,161],"no":[31],"available":[32,35],"agents":[33],"are":[34],"for":[36,226,252],"NRAS,":[37],"NF1,":[38],"CDKN2A,":[39],"PTEN,":[40],"and":[41,78,166,217],"TP53":[42],"mutations.":[43],"70%":[45],"tumors":[48,178,199],"have":[49],"activation":[50],"the":[52,85,110,123,126,175,213,227],"MAPK":[53],"pathway":[54],"due":[55],"or":[58,63,114,149,189,232],"NRAS":[59],"mutations,":[60],"while":[61,205],"loss":[62],"CDKN2A":[66],"occurs":[67],"in":[68,74,94,184,190],"approximately":[69],"40%":[70],"melanomas,":[72],"resulting":[73],"unregulated":[75],"MDM2-mediated":[76,90],"ubiquitination":[77,103],"degradation":[79,91],"p53.":[81],"Here,":[82],"we":[83,134],"investigated":[84],"therapeutic":[86],"efficacy":[87],"over-riding":[89],"p53":[93],"an":[97,223,248],"MDM2":[98,102,111,127],"that":[100],"interrupts":[101],"p53,":[105],"treating":[106],"tumor-bearing":[107],"mice":[108],"alone":[113,188,204],"combined":[115],"MAPK-targeted":[117],"therapy.":[118],"Experimental":[119],"Design:":[120],"To":[121],"characterize":[122],"ability":[124],"antagonist,":[128],"KRT-232,":[129],"inhibit":[131],"tumor":[132],"growth,":[133,158],"established":[135],"patient-derived":[136],"xenografts":[137],"(PDX)":[138],"from":[139],"15":[140,176],"melanoma.":[143],"Mice":[144],"were":[145,169],"treated":[146],"KRT-232":[148,187,202,216,221,245],"a":[150,209],"combination":[151,191,214,239],"and/or":[154,194,242],"MEK":[155,195,243],"inhibitors.":[156,196,219],"Tumor":[157],"gene":[159],"as":[162,164],"well":[163],"protein":[165],"protein\u2013phosphoprotein":[167],"changes,":[168],"analyzed.":[170],"Results:":[171],"One-hundred":[172],"percent":[173],"PDX":[177],"exhibited":[179,208],"significant":[180],"growth":[181],"inhibition":[182],"either":[183,230],"response":[185,211],"Only":[197],"BRAFV600WT":[198],"responded":[200],"treatment":[203,228,250],"BRAFV600E/M":[206],"PDXs":[207],"synergistic":[210],"BRAF/MEK":[218],"Conclusions:":[220],"effective":[224,249],"BRAFWT":[231],"PANWT":[233],"(BRAFWT,":[234],"NRASWT)":[235],"TP53WT":[236],"melanomas.":[237],"In":[238],"inhibitors,":[244],"may":[246],"be":[247],"strategy":[251],"BRAFV600-mutant":[253],"tumors.":[254]},"counts_by_year":[],"updated_date":"2026-10-13T10:08:12.033832","created_date":"2023-04-05T00:00:00"}